GLPBio

EX229

Catalog No.: GC31411Purity:>98.00%Synonyms: AMPK Activator 991
EX229, ein Benzimidazol-Derivat, ist ein potenter und allosterischer Aktivator der AMP-aktivierten Proteinkinase (AMPK) mit Kds von 0,06 μM, 0,06 μM und 0,51 μM fÜr α1β1γ1, α2β1γ1 bzw. α1β2γ1 in der Biolayer-Interferometrie.

Die Produkte sind ausschließlich für Forschungszwecke bestimmt. Nicht zur Anwendung am Menschen. Wir verkaufen nicht an Patienten.


EX229
Cas No.: 1219739-36-2
10mM (in 1mL DMSO)In Stock
$85.00
1
1mgIn Stock
$24.00
1
5mgIn Stock
$69.00
1
10mgIn Stock
$115.00
1
25mgIn Stock
$207.00
1
50mgIn Stock
$308.00
1

Zitate (Citations)

Für dieses Produkt sind derzeit keine Zitate verfügbar. Nachfolgend finden Sie ausgewählte Publikationen, die GlpBio-Produkte zitieren.
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

Beschreibung (Description)

EX229 is a benzimidazole derivative that functions as a potent allosteric agonist of AMP-activated protein kinase (AMPK)[1]. EX229 binds to AMPK with high specificity, exhibiting differential binding affinity for various isoforms: α1β1γ1 (Kd=0.06μM), α2β1γ1 (Kd=0.06μM), and α1β2γ1 (Kd=0.51μM)[2]. EX229 effectively regulates glucose transport and inhibits lipogenesis[3].

In vitro, treatment of C2C12 myotube cells with EX229 (2–25μM) for 12 hours significantly activated the AMPK signaling pathway, as indicated by a dose-dependent increase in AMPKα phosphorylation. This was accompanied by upregulation of key unfolded protein response (UPR) markers, including ATF4 and CHOP, at the protein level[4].

In vivo, daily intramuscular administration of EX229 (2.0mg/kg) for 8 weeks in a rat model of heart failure induced by coronary artery ligation significantly reversed the cardioprotective effects of Fuyu Decoction. This was demonstrated by a marked increase in left ventricular end-diastolic volume (LVEDV) and end-systolic volume (LVESV), along with a significant reduction in left ventricular ejection fraction (LVEF) and fractional shortening (LVFS)[5].

References:
[1] Lai YC, Kviklyte S, Vertommen D, et al. A small-molecule benzimidazole derivative that potently activates AMPK to increase glucose transport in skeletal muscle: comparison with effects of contraction and other AMPK activators. Biochem J. 2014 Jun 15;460(3):363-75.
[2] Xiao B, Sanders MJ, Carmena D, et al. Structural basis of AMPK regulation by small molecule activators. Nat Commun. 2013;4:3017.
[3] Bultot L, Jensen TE, Lai YC, et al. Benzimidazole derivative small-molecule 991 enhances AMPK activity and glucose uptake induced by AICAR or contraction in skeletal muscle. Am J Physiol Endocrinol Metab. 2016 Oct 1;311(4):E706-E719.
[4] Gong J, Wang L, Tao W, et al. AMPK Mediates Early Activation of the Unfolded Protein Response through a Positive Feedback Loop in Palmitate-Treated Muscle Cells. Front Biosci (Landmark Ed). 2023 Aug 7;28(8):159.
[5] Ma J, Xu Z, Zhu J, et al. Fuyu Decoction improves ventricular remodeling in rats with heart failure by inhibiting AMPK/mTOR pathway-mediated autophagy. Nan Fang Yi Ke Da Xue Xue Bao. 2023 Mar 20;43(3):466-473. 

Protokoll (Protocol)

Cell experiment [1]:

Cell lines

C2C12 myotubes (mouse skeletal muscle cell line)

Preparation Method

C2C12 myoblasts were differentiated into myotubes in high-glucose DMEM supplemented with 2% horse serum for 4 days. Myotubes were treated with EX229 at concentrations ranging from 2 to 25μM for 12 hours.

Reaction Conditions

2-25μM; 12 hours

Applications

EX229 dose-dependently activated AMPK signaling, as evidenced by increased phosphorylation of AMPKα (p-AMPKα). This activation subsequently induced the unfolded protein response (UPR), marked by upregulated protein expression of UPR markers ATF4 and CHOP. EX229 also enhanced the mRNA levels of UPR-related genes, including BIP, ATF4, GADD34, and XBP1s, demonstrating EX229 role in promoting ER stress adaptation.

Animal experiment [2]:

Animal models

Male Wistar rats with heart failure induced by ligation of the left anterior descending coronary artery

Preparation Method

Rats were treated with EX229 (2.0mg/kg) via daily intramuscular injection for 8 weeks, starting 4 weeks after heart failure induction. The treatment was combined with Fuyu Decoction (5.0g/kg, oral gavage) in the Fuyu Soup+EX229 group.

Dosage form

2.0mg/kg; i.m.

Applications

EX229 administration significantly reversed the cardioprotective effects of Fuyu Decoction, exacerbating heart failure progression. EX229 increased left ventricular end-diastolic volume (LVEDV) and end-systolic volume (LVESV), reduced ejection fraction (LVEF) and fractional shortening (LVFS), and worsened ventricular remodeling indicators. EX229 also amplified myocardial infarction area, promoted cardiomyocyte apoptosis, and enhanced autophagy activation via the AMPK/mTOR pathway, as evidenced by upregulated p-AMPK, LC3-II/LC3-I, and Beclin1 expressions, and suppressed p-mTOR and p62 levels.

References:
[1] Gong J, Wang L, Tao W, et al. AMPK Mediates Early Activation of the Unfolded Protein Response through a Positive Feedback Loop in Palmitate-Treated Muscle Cells. Front Biosci (Landmark Ed). 2023 Aug 7;28(8):159.
[2] Ma J, Xu Z, Zhu J, et al. Fuyu Decoction improves ventricular remodeling in rats with heart failure by inhibiting AMPK/mTOR pathway-mediated autophagy. Nan Fang Yi Ke Da Xue Xue Bao. 2023 Mar 20;43(3):466-473. 

Produktdokumente (Product Documents)

Purity:>98.00%Appearance:A solid

Chemische Eigenschaften (Chemical Properties)

CAS-Nr.
1219739-36-2
Synonyme
AMPK Activator 991
SMILES
O=C(O)C1=CC(OC2=NC3=CC(Cl)=C(C4=CC5=C(N(C)C=C5)C=C4)C=C3N2)=CC=C1C
Summenformel
C24H18ClN3O3
Molekulargewicht
431.87
Löslichkeit
DMSO : 5.4 mg/mL (12.50 mM)
Lagerung
Store at -20°C
Allgemeine Hinweise
Wählen Sie anhand der Löslichkeitsdaten des Produkts ein geeignetes Lösungsmittel. Aliquotieren Sie die Stammlösung nach der Herstellung, um wiederholte Gefrier-Auftau-Zyklen zu vermeiden.
Verwenden Sie Stammlösungen bei Lagerung bei -80°C innerhalb von 6 Monaten bzw. bei -20°C innerhalb von 1 Monat.
Zur Verbesserung der Löslichkeit das Röhrchen auf 37°C erwärmen und für eine angemessene Dauer beschallen.
Versandbedingungen
Evaluierungsmuster werden mit Kühlakkus versandt. Andere verfügbare Größen werden bei Raumtemperatur oder auf Anfrage mit Kühlakkus versandt.

Rechner (Calculators)Molarität / Verdünnung / Molekulargewicht / Einheitenumrechnung / In-vivo-Formulierung / Löslichkeit

g/mol

Reviews

Review for EX229

Rating: 5
  • 5 Star100%
  • 4 Star0%
  • 3 Star0%
  • 2 Star0%
  • 1 Star0%